Private Advisor Group’s Alaunos Therapeutics TCRT Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q1 | – | Sell |
-452
| Closed | -$4.79K | – | 2413 |
|
|
2023
Q4 | $4.79K | Sell |
452
-187
| -29% | -$2.25K | ﹤0.01% | 2222 |
|
|
2023
Q3 | $12.6K | Sell |
639
-83
| -11% | -$3.58K | ﹤0.01% | 2153 |
|
|
2023
Q2 | $48.8K | Sell |
722
-22
| -3% | -$1.78K | ﹤0.01% | 1965 |
|
|
2023
Q1 | $70.3K | Sell |
744
-6
| -0.8% | -$571 | ﹤0.01% | 1891 |
|
|
2022
Q4 | $56.1K | Sell |
750
-46
| -6% | -$6.67K | ﹤0.01% | 941 |
|
|
2022
Q3 | $206K | Sell |
796
-85
| -10% | -$24.7K | ﹤0.01% | 1667 |
|
|
2022
Q2 | $163K | Sell |
881
-733
| -45% | -$70K | ﹤0.01% | 1885 |
|
|
2022
Q1 | $158K | Buy |
1,614
+57
| +4% | +$7.32K | ﹤0.01% | 1940 |
|
|
2021
Q4 | $254K | Sell |
1,557
-757
| -33% | -$166K | ﹤0.01% | 1813 |
|
|
2021
Q3 | $631K | Buy |
2,314
+821
| +55% | +$251K | ﹤0.01% | 1400 |
|
|
2021
Q2 | $591K | Sell |
1,493
-358
| -19% | -$167K | 0.01% | 1311 |
|
|
2021
Q1 | $1M | Buy |
1,851
+90
| +5% | +$56K | 0.01% | 1007 |
|
|
2020
Q4 | $665K | Buy |
1,761
+411
| +30% | +$163K | 0.01% | 1083 |
|
|
2020
Q3 | $576K | Buy |
1,350
+47
| +4% | +$20.8K | 0.01% | 1003 |
|
|
2020
Q2 | $641K | Sell |
1,303
-31
| -2% | -$13.8K | 0.01% | 920 |
|
|
2020
Q1 | $490K | Buy |
1,334
+3
| +0.2% | +$1.55K | 0.01% | 902 |
|
|
2019
Q4 | $942K | Buy |
1,331
+9
| +0.7% | +$6.19K | 0.01% | 783 |
|
|
2019
Q3 | $865K | Buy |
1,322
+688
| +109% | +$546K | 0.01% | 859 |
|
|
2019
Q2 | $554K | Buy |
634
+153
| +32% | +$105K | 0.01% | 993 |
|
|
2019
Q1 | $278K | Sell |
481
-460
| -49% | -$192K | 0.01% | 1230 |
|
|
2018
Q4 | $264K | Buy |
941
+167
| +22% | +$66K | 0.01% | 1067 |
|
|
2018
Q3 | $372K | Buy |
+774
| New | +$332K | 0.01% | 1120 |
|
|
2018
Q2 | – | Sell |
-596
| Closed | -$351K | – | 1444 |
|
|
2018
Q1 | $351K | Buy |
+596
| New | +$371K | 0.01% | 816 |
|
|
2017
Q4 | – | Sell |
-324
| Closed | -$292K | – | 1394 |
|
|
2017
Q3 | $292K | Buy |
324
+18
| +6% | +$16K | 0.01% | 1156 |
|
|
2017
Q2 | $271K | Buy |
306
+29
| +10% | +$28.4K | 0.01% | 1116 |
|
|
2017
Q1 | $260K | Buy |
277
+53
| +24% | +$49.4K | 0.01% | 1151 |
|
|
2016
Q4 | $182K | Sell |
224
-126
| -36% | -$114K | 0.01% | 1167 |
|
|
2016
Q3 | $296K | Sell |
350
-146
| -29% | -$117K | 0.01% | 836 |
|
|
2016
Q2 | $444K | Buy |
496
+47
| +10% | +$51.2K | 0.02% | 674 |
|
|
2016
Q1 | $500K | Buy |
449
+193
| +75% | +$198K | 0.02% | 579 |
|
|
2015
Q4 | $319K | Buy |
+256
| New | +$423K | 0.02% | 761 |
|
Other funds holding TCRT
MP
CB
ACM
Private Advisor Group's TCRT Position: Q1 2024 in Review
Private Advisor Group sold out of Alaunos Therapeutics (TCRT) in Q1 2024, closing a stake of 452 shares — an estimated $4.79K sold.
Private Advisor Group first reported a position in TCRT in Q4 2015 and held it in 31 quarters. The position peaked at $1M in Q1 2021. 45 funds tracked by Wall St. Rank hold TCRT as of Q1 2024.
- Private Advisor Group reported no remaining Alaunos Therapeutics position as of Q1 2024 after selling out during the quarter.
- Private Advisor Group sold 452 Alaunos Therapeutics shares in Q1 2024, an estimated $4.79K.
- Private Advisor Group first reported a position in Alaunos Therapeutics in Q4 2015 and held it in 31 quarters.
- Private Advisor Group's Alaunos Therapeutics position peaked at $1M in Q1 2021.
- 45 funds tracked by Wall St. Rank held Alaunos Therapeutics as of Q1 2024.
Based on Private Advisor Group's 13F filing for Q1 2024, filed 30 Apr 2024.